معرفی
Anida Velagic is a Research Fellow in the Drug Discovery Biology department at Monash University. Her work focuses on cardiovascular pharmacology, diabetes-associated cardiovascular complications, and the role of nitric oxide (NO) and nitroxyl (HNO) in therapeutic interventions. She investigates novel treatments for diabetes-induced cardiovascular diseases, including IRAP inhibition and nitroxyl-based agents like Angeli's salt. Her research contributes to the UN Sustainable Development Goals related to good health and well-being (SDG 3).
Key research areas include understanding how high-sucrose and high-fat diets exacerbate diabetic cardiomyopathy, nitric oxide resistance in diabetic vasculature, and redox signaling mechanisms in cardiovascular dysfunction. Her studies utilize rat models to explore therapeutic targets and drug mechanisms. Velagic collaborates with international teams across pharmacology and cardiology, publishing in journals such as the American Journal of Physiology and British Journal of Pharmacology.
Her work emphasizes translational research with potential clinical applications in cardiovascular disease management. Despite her prolific output (7+ publications from 2020–2024), no specific grants or lab affiliations are explicitly detailed in the provided text.
